Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

NCT05344833 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT05344833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05344833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Lead sponsor
University of Illinois at Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
January 5, 2023
Completion date
December 31, 2030
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma